RO7296682

DB17531InvestigationalProtein Based Therapies

RO7296682 is a monoclonal antibody against CD25 (IL-2R alpha) expressed on tumour-infiltrating regulatory T (Treg) cells. RO7296682 is under investigation in clinical trial NCT04642365 (A Study to Evaluate the Safety...

Mechanism: Pharmacologically active on Interleukin-2 receptor subunit alpha
Curator reviewed
Code names: RG-6292 · RO7296682

Resolves to

Compound

UNIIHV8TQI2IKP

Targets

P01589IL2RA

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with RO7296682, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account